252873-35-1

Basic information

• Product Name: (3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate
• Synonyms: (3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate;rel-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl 4-nitrophenyl carbonic acid ester;(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (4-nitrophenyl) carbonate(WXC02226)
• CAS NO: 252873-35-1
• Molecular Formula: C13H13NO7
• Molecular Weight: 295.24482
• EINECS: -0
• Mol File: 252873-35-1.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Density: 1.45
• CAS DataBase Reference: (3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate(252873-35-1)
• EPA Substance Registry System: (3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate(252873-35-1)

Safety Data

• Hazardous Substances Data: 252873-35-1(Hazardous Substances Data)

Usage

General Description

The chemical "(3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate" is a compound with a complex molecular structure. It consists of a furofuran ring, a nitrophenyl group, and a carbonate functional group. The furofuran ring is a six-membered ring with an oxygen atom, and the nitrophenyl group contains a nitro (NO2) group attached to a phenyl ring. The carbonate functional group consists of a carbon atom bonded to three oxygen atoms, with one of the oxygens bonded to the furofuran ring. (3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate may have potential applications in pharmaceuticals, materials, or other fields, but further research and testing would be needed to determine its specific uses and properties.

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 156928-09-5 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 
• 156928-10-8 (3S,3aR,6aS)-3-hydroxyhexahydrofuro<2,3-b>furan 
• 640289-34-5 hexahydrofuro[2,3-b]furan-3-yl acetate 
• 1378929-91-9 ethyl 2-(2-ethoxy-tetrahydrofuran-3-yl)-2-oxoacetate 
• 109789-19-7 hexahydrofuro[2,3-b]furan-3-ol 
• 1378929-89-5 ethyl 2-(3-bromo-2-ethoxytetrahydrofuran-3-yl)-2-oxoacetate 
• 96406-00-7 (4,5-Dihydro-3-furanyl)glyoxylsaeure-ethylester 
• 58399-67-0 (3aR,4S,6aR)-4-(hydroxymethyl)tetrahydrofuro[3,4-b]furan-2(3H)-one 
• 80923-96-2 ((3aR,4S,6aR)-2-oxohexahydrofuro[3,4-b]furan-4-yl)methyl benzoate 
• 1008743-57-4 3-deoxy-3-(2-ethoxy-2-oxoethyl)-1,2-O-isopropylidene-α-D-ribo-pentodialdo-1,4-furanose 
• 950583-17-2 (Z)-ethyl 2-((3aR,5S,6aR)-5-((R)-1,2-dihydroxyethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ylidene)acetate 
• 57466-98-5 (Z)-ethyl 2-((3aR,5S,6aR)-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethylfuro[2,3-d][1,3]dioxol-6(3aH,5H,6aH)-ylidene)acetate 

Downstream Products

• 206361-99-1 darunavir 
• 206361-99-1 darunavir 
• 622866-41-5 trifluoromethanesulfonic acid 4-(2S,3R)-{2-([2R,3S]-hexahydro-furo[2,3-b]furan-(3R)-3-yloxycarbonylamino)-3-hydroxy-4-[N-isobutyl-(N-methoxybenzenesulfonyl)-amino]-butyl}-phenyl ester 
• 622866-42-6 {(1S,2R)-[1-(4-formyl-benzyl)]-(2R)-2-hydroxy-3-[N-isobutyl-(N-4-methoxy-benzenesulfonyl)-amino]-propyl}-carbamic acid [3R,3aS,6aR]-hexahydrofuro[2,3-b]furan-3-yl ester 
• 605654-10-2 {[1S,2R]-2-hydroxy-1-(4-hydroxy-benzyl)-3-[N-isobutyl-(N-4-methoxybenzenesulfonyl)-amino]-propyl}-carbamic acid hexahydro-[3R,3aS,6aR]-furo[2,3-b]furan-3-yl ester 
• 186487-59-2 {(1S,3S,4S)-1-Benzyl-4-[(3S,3aR,6aS)-(hexahydro-furo[2,3-b]furan-3-yl)oxycarbonylamino]-3-hydroxy-5-phenyl-pentyl}-carbamic acid tert-butyl ester 
• 186487-62-7 {(1S,3S,4S)-1-Benzyl-4-[(3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl)oxycarbonylamino]-3-hydroxy-5-phenyl-pentyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

The Chiron Approach to (3 R,3 aS,6 aR)-Hexahydrofuro[2,3- b]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir

We describe an enantioselective synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol which is a key subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2-O-isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-aldehyde derivative. This optically active ligand alcohol was converted to darunavir efficiently.

CRYSTALLINE DARUNAVIR

The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.

Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance

Summary The rapid evolution of HIV under selective drug pressure has led to multidrug resistant (MDR) strains that evade standard therapies. We designed highly potent HIV-1 protease inhibitors (PIs) using the substrate envelope model, which confines inhib